Skip to main content
Premium Trial:

Request an Annual Quote

Igenica Raises $24M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Igenica today said it has completed a Series B financing round, raising $24 million.

The round was led by The Column Group, OrbiMed Advisors, and 5AM Ventures. The funds will be used to expand and accelerate Igenica's drug discovery and development efforts using its proteomics- and antibody-based platforms, Igenica said in a statement.

The proteomics platform, called sTAg, identifies new surface antigens that are amenable to antibody targeting in cancer. The monoclonal antibody platform, called iTAb, is a function-based de novo method for generating and screening antibody drug candidates against tumor antigens.

Based in Burlingame, Calif., Igenica previously had raised about $5 million.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.